Orgenesis Inc. (NASDAQ:ORGS – Get Free Report) traded up 68.6% during trading on Monday . The company traded as high as $0.59 and last traded at $0.59. 102 shares were traded during mid-day trading, a decline of 89% from the average daily volume of 971 shares. The stock had previously closed at $0.35.
Orgenesis Stock Performance
The company’s fifty day simple moving average is $0.27 and its two-hundred day simple moving average is $0.36. The stock has a market capitalization of $3.05 million, a PE ratio of -0.05 and a beta of 3.16.
About Orgenesis
Orgenesis, Inc is a cell and gene therapy company that develops and commercializes point-of-care manufacturing platforms for autologous and allogeneic therapies. The company offers an end-to-end solution that spans from R&D through clinical and commercial production, targeting applications in oncology, neurology, and various rare diseases. Orgenesis’ technology platforms are designed to streamline the complex processes involved in cell isolation, genetic modification, expansion and cryopreservation.
The company’s flagship offering is its automated Prodigy® platform, which integrates cell processing workflows into a closed, single-use system.
Further Reading
- Five stocks we like better than Orgenesis
- Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
- 3 Dividend Kings to Buy While They’re Still Beaten Down
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.
